SORRENTO THERAPEUTICS WKN: A1W8DY ISIN: US83587F2020 Kürzel: SRNE Forum: Aktien Thema: Hauptdiskussion

Bis nächstes Jahr geimpft werden kann ist Frühling und corona erst mal wieder durch. Ob die ihren Impfstoff wirklich so los werden wie die alle glauben bin ich mal gespannt. Noch dazu gibt immer mehr regionen wo Herden Immunität auftritt

Und Adler muss nur einmal scrollen bis zum 1. Kommentar

Krass

Schaffen wir heute die 30.000?

😁🌶

🙄🙄🙄

Was willst du denn hier? Stunkt machen?

Garantiert nicht!

Sorrento KAUFEN?

🤣

Wer hat bei 6 Euro verkauft und kauft jetzt wieder nach?

Ist fast dunkel. ElaSusi hat keine Taschenlampe für den Heimweg.

Cu

So, für heute sag ich mal tschüß allen :)

Sry er nahm den link nicbt an 😁

SearchGo Novavax and Sorrento Therapeutics: Are These Beaten-Down Coronavirus Stocks a Bargain? Novavax and Sorrento Therapeutics have been on a sharp downward trajectory. George Budwell (TMFGBudwell) Nov 16, 2020 at 10:00AM Author Bio COVID-19 stocks have been a hot commodity in 2020. Several companies with anti-coronavirus assets such as antibodies, diagnostics, and vaccines, in fact, have seen their share prices rise by more than 1,000% this year. Even though the outbreak is as strong as ever in countries like the United States, however, a fair number of these former red-hot stocks have pulled back in a big way from their 52-week highs. This near nichewide correction appears to stem from a slew of factors including the recent approval of Eli Lilly's COVID-19 antibody drug bamlanivimab, the likely approval of Pfizer and BioNTech's mRNA COVID-19 vaccine in the coming weeks, and the lack of a second stimulus relief bill which may have provided additional funding for research and development.  IMAGE SOURCE: GETTY IMAGES. Novavax (NASDAQ:NVAX) and Sorrento Therapeutics (NASDAQ:SRNE) have both been hit especially hard by this reversion to the mean among COVID-19 stocks. Novavax's shares have lost 46% over their value since hitting an all-time high back in August. Sorrento's stock, on the other hand, is down by a whopping 66% from its 52-week high at the time of writing. Should bargain hunters pounce on these beaten-down COVID-19 stocks? Let's take a look at the core value proposition of each company to find out.  Novavax: Is a rebound in the cards? Novavax's COVID-19 product candidate is a recombinant protein based vaccine known as NVX-CoV2373. The biotech has an going late-stage trial for the vaccine in the U.K., along with another planned pivotal stage study set to kick off in the U.S. by the end of November. Novavax has received financial support from the federal government's Operation Warp Speed to accelerate the vaccine's development, as well as regulatory support from the Food and Drug Administration via a Fast Track designation for NVX-CoV2373. The first interim data from the vaccine's late-stage program could become public knowledge within the first quarter of 2021. What this all means is that Novavax has a good shot at bringing the third or perhaps fourth novel coronavirus vaccine to market within the Western Hemisphere. In anticipation of an accelerated approval, the biotech has also been bulking up its manufacturing capabilities through both acquisitions and third-party deals over the past few months.  What's the risk? There are three key risks investors should consider with this mid-cap biotech. First, Novavax's vaccine may flat out fail in late-stage trials, despite encouraging preclinical and early stage data. Second, the company has never handled a regulatory application or a commercial launch. Third, Novavax's vaccine -- if approved -- may have a hard time competing in this jam-packed space, especially if the mRNA vaccine candidates from Pfizer/BioNTech and Moderna do indeed sport truly outstanding levels of efficacy.  What's the key takeaway? There are far too many unknowns to draw any solid conclusions about the biotech's near-term prospects right now. As such, it might be best for aggressive investors to simply pencil in Novavax as a strong watchlist candidate for the time being. That's not to say that a turnaround isn't a real possibility, but the company definitely needs some luck on several key fronts to spark a rebound.       Sorrento: Is an inflection point near? Sorrento has quickly ratcheted up its research and development apparatus this year to become a one stop shop for all things COVID-19. Specifically, the biotech has a vaccine under development, neutralizing antibodies in the clinic, multiple molecular diagnostics in the pipeline, and a rescue therapy -- abivertinib -- in phase 2 development. Despite this flurry of clinical development, however, Sorrento isn't widely considered a leader inhh any of these therapeutic areas for the pandemic.  Eli Lilly and Regeneron Pharma